Greenwich Lifesciences Stock Buy Hold or Sell Recommendation
| GLSI Stock | USD 12.00 0.22 1.87% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Greenwich Lifesciences is 'Hold'. The recommendation algorithm takes into account all of Greenwich Lifesciences' available fundamental, technical, and predictive indicators you will find on this site.
Check out Greenwich Lifesciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide. In addition, we conduct extensive research on individual companies such as Greenwich and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
Greenwich |
Execute Greenwich Lifesciences Buy or Sell Advice
The Greenwich recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Greenwich Lifesciences. Macroaxis does not own or have any residual interests in Greenwich Lifesciences or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Greenwich Lifesciences' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Greenwich Lifesciences Trading Alerts and Improvement Suggestions
| Greenwich Lifesciences generated a negative expected return over the last 90 days | |
| Greenwich Lifesciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (8.89 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Greenwich Lifesciences currently holds about 15.64 M in cash with (6.48 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22. | |
| Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 53.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Jaye Thompson of 149818 shares of Greenwich Lifesciences at 12.16 subject to Rule 16b-3 |
Greenwich Lifesciences Returns Distribution Density
The distribution of Greenwich Lifesciences' historical returns is an attempt to chart the uncertainty of Greenwich Lifesciences' future price movements. The chart of the probability distribution of Greenwich Lifesciences daily returns describes the distribution of returns around its average expected value. We use Greenwich Lifesciences price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Greenwich Lifesciences returns is essential to provide solid investment advice for Greenwich Lifesciences.
| Mean Return | -0.16 | Value At Risk | -5.13 | Potential Upside | 4.54 | Standard Deviation | 2.93 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Greenwich Lifesciences historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Greenwich Stock Institutional Investors
| Shares | Strs Ohio | 2024-09-30 | 12.8 K | Bank Of New York Mellon Corp | 2024-12-31 | 11.2 K | Barclays Plc | 2024-12-31 | 9.6 K | Bank Of America Corp | 2024-12-31 | 7.3 K | Jpmorgan Chase & Co | 2024-12-31 | 7.1 K | Ubs Group Ag | 2024-12-31 | 6.6 K | Rhumbline Advisers | 2024-12-31 | 6.5 K | New York State Common Retirement Fund | 2024-12-31 | 6 K | Citigroup Inc | 2024-12-31 | 4.9 K | Blackrock Inc | 2024-12-31 | 357.8 K | Vanguard Group Inc | 2024-12-31 | 275 K |
Greenwich Lifesciences Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 28.7M | (1.5M) | (13.7M) | (6.5M) | (5.8M) | (5.5M) | |
| Free Cash Flow | (1.2M) | (4.3M) | (6.2M) | (6.5M) | (5.8M) | (5.5M) | |
| Net Income | (1.9M) | (4.6M) | (7.8M) | (8.9M) | (8.0M) | (7.6M) | |
| End Period Cash Flow | 28.7M | 27.2M | 13.5M | 7.0M | 8.0M | 14.0M | |
| Other Non Cash Items | 777.8K | 1.2M | 1.8M | 35.5K | 40.8K | 38.8K |
Greenwich Lifesciences Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Greenwich Lifesciences or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Greenwich Lifesciences' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Greenwich stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.02 | |
β | Beta against Dow Jones | 1.10 | |
σ | Overall volatility | 2.99 | |
Ir | Information ratio | -0.01 |
Greenwich Lifesciences Volatility Alert
Greenwich Lifesciences exhibits very low volatility with skewness of 0.34 and kurtosis of 1.38. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Greenwich Lifesciences' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Greenwich Lifesciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Greenwich Lifesciences Fundamentals Vs Peers
Comparing Greenwich Lifesciences' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Greenwich Lifesciences' direct or indirect competition across all of the common fundamentals between Greenwich Lifesciences and the related equities. This way, we can detect undervalued stocks with similar characteristics as Greenwich Lifesciences or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Greenwich Lifesciences' fundamental indicators could also be used in its relative valuation, which is a method of valuing Greenwich Lifesciences by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Greenwich Lifesciences to competition |
| Fundamentals | Greenwich Lifesciences | Peer Average |
| Return On Equity | -1.52 | -0.31 |
| Return On Asset | -0.9 | -0.14 |
| Current Valuation | 149.02 M | 16.62 B |
| Shares Outstanding | 13.14 M | 571.82 M |
| Shares Owned By Insiders | 53.05 % | 10.09 % |
| Shares Owned By Institutions | 8.44 % | 39.21 % |
| Number Of Shares Shorted | 653.14 K | 4.71 M |
| Price To Book | 31.08 X | 9.51 X |
| EBITDA | (9.32 M) | 3.9 B |
| Net Income | (8.89 M) | 570.98 M |
| Cash And Equivalents | 15.64 M | 2.7 B |
| Cash Per Share | 1.22 X | 5.01 X |
| Total Debt | 294.41 K | 5.32 B |
| Current Ratio | 65.74 X | 2.16 X |
| Book Value Per Share | 0.38 X | 1.93 K |
| Cash Flow From Operations | (6.48 M) | 971.22 M |
| Short Ratio | 31.07 X | 4.00 X |
| Earnings Per Share | (0.81) X | 3.12 X |
| Target Price | 38.0 | |
| Number Of Employees | 3 | 18.84 K |
| Beta | 3.32 | -0.15 |
| Market Capitalization | 154.84 M | 19.03 B |
| Total Asset | 6.99 M | 29.47 B |
| Retained Earnings | (50.36 M) | 9.33 B |
| Working Capital | 6.7 M | 1.48 B |
| Net Asset | 6.99 M |
Note: Acquisition by Jaye Thompson of 149818 shares of Greenwich Lifesciences at 12.16 subject to Rule 16b-3 [view details]
Greenwich Lifesciences Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Greenwich . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 271.89 | |||
| Daily Balance Of Power | 0.7586 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 11.92 | |||
| Day Typical Price | 11.94 | |||
| Price Action Indicator | 0.2 | |||
| Period Momentum Indicator | 0.22 |
About Greenwich Lifesciences Buy or Sell Advice
When is the right time to buy or sell Greenwich Lifesciences? Buying financial instruments such as Greenwich Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Greenwich Lifesciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Funds Thematic Idea Now
Consumer Funds
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Greenwich Lifesciences Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.